Twist Bioscience Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 41 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 63.62.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Twist Bioscience Corp is 7.67, ranking 94 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 110.72M, representing a year-over-year increase of 19.31%, while its net profit experienced a year-over-year increase of 11.93%.
Key Metrics
The current valuation score of Twist Bioscience Corp is 7.58, ranking 61 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -37.28, which is -91.83% below the recent high of -3.05 and -34.10% above the recent low of -50.00.
The current earnings forecast score of Twist Bioscience Corp is 8.55, ranking 30 out of 155 in the Pharmaceuticals industry. The average price target is 36.00, with a high of 57.17 and a low of 32.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Twist Bioscience Corp is 6.76, ranking 82 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 60.82 and the support level at 42.76, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Twist Bioscience Corp is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 126.03%, representing a quarter-over-quarter increase of 4.81%. The largest institutional shareholder is Catherine Wood, holding a total of 6.34M shares, representing 10.19% of shares outstanding, with 2.22% decrease in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Twist Bioscience Corp is 4.71, ranking 84 out of 155 in the Pharmaceuticals industry. The company's beta value is 2.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
